The *Drosophila* Fos-related AP-1 protein is a developmentally regulated transcription factor

Karen K. Perkins, Arie Admon, Nipam Patel, and Robert Tjian

Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Division of Biochemistry and Molecular Biology, University of California, Berkeley, California 94720 USA

*Drosophila* AP-1 consists of two proteins (dFRA and dJRA) that have functional and structural properties in common with mammalian Fos and Jun proto-oncogene products. Here, we report the isolation and characterization of cDNAs encoding the full-length dFRA and dJRA proteins. The predicted amino acid sequences reveal that both proteins contain a bipartite DNA-binding domain consisting of a leucine repeat and an adjacent basic region, which are characteristic of members of the AP-1 family. By using protein translated in vitro or expressed in *Escherichia coli*, we demonstrate that dFRA, in contrast to the mammalian cFos proteins, recognizes the AP-1 site on its own and activates transcription in vitro in the absence of dJRA or Jun. Heteromeric complexes formed between dFRA and dJRA bind the AP-1 site better than either protein alone, and the two proteins activate transcription synergistically in vitro. In the developing embryo, dFRA mRNA is first expressed in a limited set of cells in the head and is later restricted to a subset of peripheral neurons, several epidermal cells near the muscle attachment sites, and a portion of the gut. In contrast, dJRA appears to be uniformly expressed at a low level in all cell types. These results indicate that dFRA is a developmentally regulated transcription factor and suggest that its potential interplay with dJRA plays an important role in cell-type-specific transcription during *Drosophila* embryonic development.

[Key Words: *Drosophila*, transcription, AP-1]

Received January 26, 1990; revised version accepted February 28, 1990.

A knowledge of the normal functions of proto-oncogenes in cell growth and differentiation and the mechanisms by which they act are central to an understanding of oncogenesis. *Drosophila* has been particularly useful for discerning the normal roles of proto-oncogenes in development. A number of *Drosophila* proto-oncogene homologs, such as *src, ras, erb-B, rel,* and *int-1*, display cell-type-specific expression or have been shown to affect certain developmental stages. In some cases, a corresponding mutation in the gene has been isolated, enabling the unambiguous identification of the biological processes in which these proto-oncogenes are involved [for review, see Adamson 1987; Bender and Peifer 1987; Shilo 1987; Steward 1987; Bishop and Corces 1988; Schejter and Shilo 1989].

A wealth of evidence, accumulated from studies of a variety of organisms, indicates that the products of proto-oncogenes fulfill their biological functions by participating in different stages of signal transduction, thereby governing the ability of cells to respond to external cues. For example, many proto-oncogene products have been shown to transmit signals via protein phosphorylation and are either receptors, such as Erb-B, or membrane-associated cytoplasmic proteins, such as the *src* gene product. Some membrane-associated oncoproteins, such as those of the Ras family, hydrolyze GTP, triggering a cascade of subsequent regulatory events. Other oncoproteins, such as Myc and Fos, are localized in the nucleus and have been implicated in gene regulation (Curran and Franza 1988; for review, see Hanley 1988).

The transient expression of Fos is one of the earliest known responses to numerous external stimuli, such as TPA, and serum and calcium ionophores, which activate distinct pathways in both differentiated and nondifferentiated cell types. In addition, Fos has been found to be associated with chromatin. These results originally suggested that Fos was a nuclear target for signal transduction whose transient induction triggered the expression of specific genes. The expression of Fos has also been observed in a spatially restricted fashion during mouse embryonic development and appears to be associated with differentiating tissues [for review, see Adamson 1987].

It had long been observed that cellular Fos was complexed with a protein designated p39 (Curran and Teich 1982). The findings that p39 is the Jun oncprotein (Rauscher et al. 1988b) and that Jun is a member of the transcription factor AP-1 family (Bohmann et al. 1987) provided the first convincing link between signal trans-
duction by proto-oncogene products and transcriptional activation. The mammalian AP-1 family is now known to consist of multiple proteins [such as Fos-related antigens (FRAs), FosB, JunB, and JunD (Ryder et al. 1989; Zerial et al. 1989 and references therein)] that are related to Fos and Jun by virtue of their recognition of the AP-1-binding sequence, TGACTCA, which can also act as a TPA- and serum-inducible enhancer element (Lee et al. 1987).

It is likely that all members of the AP-1 family influence gene expression via their interactions with the AP-1 site. However, recent evidence indicates that Fos and mammalian Fos-related proteins must form heterodimeric complexes with Jun to recognize the AP-1 site. Their inability to bind the AP-1 site on their own has been attributed to the observation that they are not able to form homodimeric complexes, at least in vitro. Jun, however, can form a homodimeric complex and recognizes the AP-1 site on its own (Halazonetis et al. 1988; Rauscher et al. 1988a). The formation of these complexes is dependent on the integrity of the leucine repeat structural motifs in common with their mammalian AP-1 counterparts. Using protein expressed in Drosophila embryos (750 grams) and purified subsequently by DNA affinity chromatography, we examined the transcriptional activation properties of the Drosophila AP-1 family and genomic libraries. By this approach, we obtained the full-length dFRA and dJRA cDNAs (Fig. 1A,B). A single dJRA cDNA was isolated from ~700,000 clones in a library prepared from embryos harvested between 9 and 12 hr of development. To obtain the dFRA cDNA, we first isolated a fragment of the dJRA gene from a genomic library and then used this fragment to probe a cDNA library prepared from embryos between 3 and 12 hr of development (as described in Materials and methods).

The various Drosophila cDNAs were subcloned from phage λ into Bluescript-SK to generate dFRA–SK and dJRA–SK, which were then sequenced (Fig. 1). Within the predicted amino acid sequences of dFRA and dJRA, the tryptic peptides obtained previously were identified (Fig. 1). The dFRA–SK cDNA is 3652 bp in length and contains an open reading frame (ORF) of 1785 bp that encodes a protein of 595 amino acids. The dJRA–SK cDNA is 1178 bp in length and contains an ORF of 867 bp that encodes a protein of 289 amino acids.

By using the Drosophila AP-1 cDNAs as probes, we have localized the dFRA and dJRA genes to the regions 99B(9–10) and 46E, respectively, on polytene chromosomes [data not shown]. Although, the 46E region has not been well characterized, the claret gene is within 99B, Yamamoto et al. 1989, and Southern blot analysis has demonstrated that this gene lies within 12 kb of dFRA [data not shown].

Both dFRA and dJRA proteins share structural features with their mammalian AP-1 counterparts. The sequence of dFRA resembles that of Fos, and the sequence of dJRA resembles that of Jun. For example, the Fos basic domain responsible for enhanced DNA binding of Fos–Jun complexes (Bohmann and Tjian 1989; Turner and Tjianerahble}
Figure 1.  [Continued on facing page.]
dFRA is a transcriptional activator

**Figure 1.** DNA and amino acid sequences of dFRA and dJRA. The nucleotide sequences of the cDNAs and the amino acid sequences of the ORFs of dFRA (A) and dJRA (B) are shown. The underlined sequences correspond to the peptide sequences obtained by trypsin digestion of dFRA and dJRA. The shaded regions represent the basic motifs and leucine repeats within dFRA and dJRA ORFs. (C) The basic motifs and leucine repeats of dFRA and dJRA are compared with those of Fos and Jun, respectively. The amino acids in boxes comprise the leucine repeat. Lines connect the amino acids that are identical between the proteins, dots represent conserved amino acids.

1989) is 79% conserved in dFRA. The corresponding domain of Jun is 89% conserved in dJRA (Fig. 1C). Furthermore, the *Drosophila* AP-1 proteins also contain a leucine repeat [Fig. 1C; Landschulz et al. 1988] that is present in Fos and Jun and is required for formation of the Jun homodimer and the Fos–Jun heterodimer [Bohmann and Tjian 1989, Turner and Tjian 1989]. The dFRA leucine repeat differs from that of Fos, however, in that a methionine residue replaces the third leucine. It has been suggested that methionine at this position would not significantly alter the structural integrity of the leucine zipper [Landschulz et al. 1988].

Another structural feature in common between the *Drosophila* and mammalian AP-1 proteins is the relative positions of the basic motif and adjacent leucine repeat within the protein molecule. As in Fos, these structural features are present in the middle of dFRA, whereas they are at the carboxyl terminus in dJRA and Jun (Fig. 1A,B). Interestingly, the *Drosophila* and mammalian AP-1 proteins have few significant sequences in common within the remaining portions of the proteins. The sequences of dFRA and dJRA cDNAs and their homologies with mammalian Fos and Jun sequences, respectively, within the basic motifs and leucine repeats provide strong evidence that the cDNAs we have obtained encode *Drosophila* AP-1 proteins.

dFRA and dJRA expressed in *E. coli* each recognize the AP-1 site

We demonstrated previously that dFRA and dJRA purified from *E. coli* extracts were ~70 and 40 kD, respectively [Fig. 2A, lane 2] and that they each recognized the AP-1 site [Perkins et al. 1988]. To verify that the dFRA and dJRA cDNAs that we isolated encoded *Drosophila* AP-1 proteins, it was essential to determine that the encoded proteins possessed similar biochemical properties. Toward this aim, dFRA and dJRA proteins were produced by using an *E. coli* expression system and were purified by DEAE–Sepharose and sequence-specific DNA affinity chromatography [as described in Materials and methods]. The resulting fractions, as analyzed by SDS-PAGE, revealed that dFRA and dJRA had been purified to near homogeneity and were the same sizes as the dAP-1 proteins purified from *Drosophila* embryos [Fig. 2A, lanes 2, 5, and 6]. We have verified by Western blot analysis that purified dFRA and dJRA from bacteria cross-react with antibodies to mammalian Fos and Jun [data not shown, Perkins et al. 1988].

We next showed that dFRA and dJRA proteins purified from *E. coli* were capable of specifically recognizing the AP-1-binding site in a DNase I footprinting assay [Fig. 2B]. It was necessary to add approximately fourfold more dFRA protein than dJRA protein to the binding assay to observe a footprint. In testing the individual proteins for DNA binding, we found that the DNase I hypersensitive sites resulting from the binding of dFRA are distinct from those of dJRA [see arrows, Fig. 2B]. As expected, the hypersensitive sites resulting from dAP-1 purified from *Drosophila* embryos, which contain a mixture of dFRA and dJRA, represent the sum of the hypersensitive sites from either of these two proteins alone. These results confirm that the *Drosophila* Fos-related protein, unlike cFos from mammalian cells, is fully capable of recognizing the AP-1 site on its own, albeit with somewhat lower avidity than dJRA [Perkins et al. 1988].

Complex formation between dFRA and dJRA

Although mammalian Fos has not been demonstrated to recognize the AP-1 site on its own, it does form a heterodimeric complex with Jun that is dependent on the integrity of the leucine repeat domain [Turner and Tjian 1989]. In addition, the Fos–Jun heterodimer has a higher affinity for the AP-1 site than Jun alone [Rauscher et al. 1988a; Zerial et al. 1989]. Because we found that the *Drosophila* AP-1 proteins contained leucine repeats, it was of interest to determine whether they were capable of recognizing the AP-1 site as an oligomeric complex.

For this purpose, we employed an electrophoretic mobility-shift assay [EMSA], which can distinguish different protein complexes bound to DNA. dFRA and dJRA proteins were synthesized in vitro, separately or together, using a rabbit reticulocyte lysate. The products of the translation reaction were determined to be the proper size and to be of roughly equimolar concentrations by SDS-PAGE [data not shown]. These in vitro-synthesized proteins were incubated with a labeled oli-
Figure 2. Purification and DNA binding of dFRA and dJRA expressed in E. coli. (A) Protein fractions from various stages of the purification were subjected to 10% SDS-PAGE and visualized by silver staining. (Lane 1) Molecular weight standards [M]; (lane 2) dAP-1, purified from embryo extracts (0.2 μg of protein); (lane 3) DEAE flowthrough (FT, affinity column load, ~5 μg of protein); (lane 4) affinity FT (~1 μg of protein); (lane 5) dJRA affinity column eluate (~150 ng of protein); (lane 6) dFRA affinity column eluate (~50 ng of protein). (B) DNase I footprinting reactions were carried out as described previously and contained a probe spanning the human metallothionein IIA (hMTIIA) promoter that contains an AP-1 site (Perkins et al. 1988). Protein was added where indicated. (Lanes 8–10) dAP-1 purified from embryo (1.0, 2.0, and 3.0 ng of protein, respectively); (lanes 12–14) dFRA purified from E. coli (2.5, 12.5, and 25 ng of protein, respectively); (lanes 16–19) dJRA purified from E. coli (0.3, 3.0, and 6.0 ng of protein).

gonucleotide containing an AP-1 site, and the resulting protein–DNA complexes were separated by PAGE (see Materials and methods). We found that the combination of dFRA and dJRA is capable of forming a complex with AP-1 site DNA that has an electrophoretic mobility distinct from the complex formed either by dFRA or dJRA alone (Fig. 3). Although these experiments were carried out using dFRA and dJRA that had been cotranslated, we have evidence that cotranslation is not a requirement for formation of the dFRA–dJRA–DNA complex (data not shown).

The complex formed using the mixture of dFRA and dJRA appears to have a higher affinity for the AP-1 site than either dAP-1 protein alone, as judged by the relative amount of labeled oligonucleotide retained as the slower migrating species. In addition, the intensity of the band corresponding to the protein–DNA complex formed by dFRA is typically weaker than that formed by dJRA [Fig. 3, cf. lanes 1 and 4 with 2 and 7]. From other studies with EMSA, we have evidence that the complex generated by the binding of dFRA to the AP-1 site is more stable at temperatures below 25°C [data not shown]. These results strengthen our conclusions from DNase I footprinting data [Fig. 2B] that dFRA binds less strongly to the AP-1 site than dJRA does. Moreover, our findings indicate that dFRA and dJRA, like their mammalian counterparts, can form a heteromeric complex with enhanced DNA binding affinity.

dFRA is a transcription factor

We reported previously that dJRA, but not dFRA, activated transcription in vitro and suggested that dFRA may have been inactive due to the denaturing conditions required to purify this protein from the Drosophila embryo [Perkins et al. 1988]. Here, we have used dFRA and dJRA proteins, purified by sequence-specific DNA affinity chromatography from E. coli harboring the appropriate expression plasmids, to test their transcriptional properties, singly and in combination. For these experiments, dFRA and/or dJRA were incubated with an extract prepared from Drosophila embryos that had been depleted of dAP-1 proteins by use of an AP-1 site-specific DNA affinity resin [Perkins et al. 1988]. In the presence of a template containing four AP-1 sites, dFRA, on its own, activates transcription (~sevenfold; Fig. 4, lane 3). As expected, dJRA activates transcription to a similar extent (Fig. 4, lane 5). Furthermore, the combination of
dFRA is a transcriptional activator

Figure 3. Protein–DNA complexes formed by dFRA and dJRA. In vitro transcription and translation and DNA-binding assays were as described [see Materials and methods; Turner and Tjian 1989]. (Lanes 1–15) Various combinations of dAP-1 or human AP-1 proteins translated in vitro, as indicated; (lane 16) control: DNA-binding reaction carried out in the absence of in vitro-translated protein. The 32P-labeled and unlabeled oligonucleotides used were identical. They were blunt-ended, double-stranded, and contained the AP-1 site (top-strand sequence: 5'-GAGCCGCAAGTGACTCAGCGGGGCGTGTGCAGG-3') from the hMTIIA promoter [see Turner and Tjian 1989].

dFRA and dJRA activates transcription to a level greater than the sum of either of the two factors alone, because the mixture of half the amount of each dAP-1 protein resulted in an ~20-fold stimulation of transcription [Fig. 4, lanes 7 and 8]. No detectable activation was observed from a template that lacks AP-1 sites [Fig. 4, lanes 2, 3, and 6]. In the absence of added dAP-1 proteins, these sites did not alter the rate of transcription in the depleted extract [Fig. 4, lanes 1 and 2]. These results indicate that a Fos-related protein, dFRA, can act as a transcription factor on its own but can also function synergistically with a Jun-related protein, dJRA, to enhance transcription.

dFRA is expressed in a temporally dynamic and spatially restricted pattern during embryogenesis

As a first step toward studying the roles of dFRA and dJRA in Drosophila development, we monitored the expression of mRNA at various stages of embryogenesis. By using Northern blot analysis, we find that the temporal pattern of dFRA mRNA changes dramatically during embryonic development [Fig. 5]. It is undetectable until 4 hr after fertilization [Fig. 5, lanes 1 and 2], and present at increasingly higher levels between 4 and 12 hr [Fig. 5, lanes 3 and 4]. This high level of expression is then maintained between 12 and 16 hr of embryogenesis [Fig. 5, lane 5]. In contrast, dJRA is expressed at a relatively constant level at all stages of development [data not shown]. We estimate that the maximal levels of dFRA and dJRA expression are one-twentieth that of actin. Also, from the Northern blot, we calculate that the lengths of dFRA and dJRA mRNAs are ~3.7 and 1.7 kb, respectively. These results suggest that the dFRA cDNA may contain sequences that are very near to the 5’ end of the message.

To study the spatial pattern of dFRA and dJRA expression in the Drosophila embryo, we used in situ hybridization with both radioactive [35S-labeled RNA] and nonradioactive (digoxigenin-labeled single-stranded DNA) probes [see Materials and methods]. By using in situ hybridization, we found that dFRA mRNA expression is restricted to specific cell types and tissues in the developing embryo. For example, RNA is initially expressed within cells of the head soon after gastrulation at 4–5 hr of embryogenesis [Fig. 6 A–C]. The cells expressing dFRA in the head are likely to be mesodermal [Fig. 6B], and some of this expression is localized to a region surrounding the cephalic furrow [Fig. 6C]. This head-specific expression was observed as late as 8 hr of embryogenesis. During these early stages, dFRA mRNA expression is also observed in the dorsal ectoderm and amnioserosa [data not shown].

Later, in embryos that are older than 11 hr, dFRA ex-
Expression of a Fos-related gene in the developing embryo

Many proto-oncogenes play a role in embryonic development and are expressed in a tissue- or stage-specific fashion (Adamson 1987). The detection of AP-1 in Drosophila embryo extracts (Perkins et al. 1988) provided a starting point for studying the role of Fos- and Jun-related proteins in an organism whose development is well characterized. By using in situ hybridization, we have now charted the expression of the Drosophila AP-1 mRNA in particular cell types during development. We find that dFRA mRNA is expressed in a spatially restricted fashion in specific regions of the head (between 4 and 8 hr) and PNS (between 11 and 13 hr). The precise identities that we assigned to individual cell types of the nervous system are tentative and will require double-labeling experiments to align the patterns generated with dFRA antibodies with the patterns seen with antibodies that label all or subsets of peripheral neurons (Bodmer et...
dFRA is a transcriptional activator. Interestingly, dFRA mRNA was not detected by in situ hybridization at stages of embryogenesis between ~8 and 11 hr. Because we observe dFRA mRNA by Northern analysis, it is possible that dFRA mRNA is expressed during these stages at a low level in all cell types. In addition, dJRA mRNA was

Figure 6. In situ hybridization analysis of dFRA expression in embryos. In situ hybridization with both radioactive and nonradioactive probes at different stages of embryogenesis. [A] Horizontal section of a Drosophila embryo (4–5 hr of development) hybridized with an [α-35S]UTP-labeled RNA probe. The probe was prepared from dFRA-SK by use of T7 RNA polymerase and conditions described by Dynlacht et al. (1989). Whole-mount embryos [B–E and G] and tissue excised from a whole-mount embryo [F] were labeled by hybridization with a nonradioactive single-stranded DNA probe. [B and C] Embryos between 4 and 5 hr of development. dFRA is expressed in the head in cells that we believe to be mesodermal. Embryos [D–G] or tissue from embryos [F] between 11 and 13 hr of development is shown. [D and F] Arrows indicate expression in cells that we believe to be peripheral neurons. [F] Tissue shown is epidermis and PNS excised from an 11–13-hr embryo. [E] Arrow indicates cells that hybridize to a dFRA probe, which are located at muscle attachment sites. It appears that these cells are epidermal. [G] Arrow indicates expression in the anal pad of an 11–to 13-hr embryo. Expression is also observed in cells of the midgut and hindgut. The orientation in each panel is as follows: [B, D, and E] ventral views; [C and G] anterior left and dorsal up; the tissue [F] is ventral up.
detectable at levels of expression that were barely above background [data not shown], and we conclude that dFRA is expressed ubiquitously throughout the embryo. This is in marked contrast to the tissue-specific expression of the c-jun and junB genes during organ development in the mouse embryo (Wilkinson et al. 1989) and may reflect the involvement of mouse and Drosophila Jun proteins in distinct biological processes.

The finding that the expression of dFRA is spatially restricted is intriguing in light of the cell- and tissue-specific expression of mammalian cFos. For example, in the mouse embryo, Fos expression is restricted to extraembryonal tissues, such as the amnion and yolk sac (Deschamps et al. 1985 and references therein). In addition, a low level of Fos mRNA and protein is normally present in neuronal subpopulations of the adult rat brain and has been found to increase following exposure to a drug that induces seizures (Morgan et al. 1987; Saffan et al. 1988). Obviously, it is premature to assign a function for dFRA on the basis of its expression pattern. It is possible, however, that the expression of dFRA mRNA in the embryo reflects a role for dFRA in the expression of genes required for neurogenesis or for other developmental processes. A careful analysis of Drosophila embryos that possess mutated versions of the dFRA gene, as well as identification of the target genes for dFRA transcriptional activation, will provide additional information concerning the role of the fos-related proto-oncogene in Drosophila development.

Synergetic activation by dFRA and dJRA

A number of investigators have reported a cooperative interaction between Fos and Jun that has been observed by DNA-binding experiments using proteins translated in vitro (Halazonetis et al. 1988; Kouzarides and Ziff 1988; Nakabeppu et al. 1988, Rauscher et al. 1988a; Schuermann et al. 1989, Turner and Tjian 1989) or by transient transfection assays (Chiu et al. 1988; Sassone-Corsi et al. 1988; Schonthal et al. 1988). However, no direct in vitro evidence with purified Jun and Fos proteins has been forthcoming. We demonstrate that an in vitro transcription assay is feasible with purified Fos and Jun-related proteins from Drosophila. We present new evidence that a protein related to Fos can activate transcription autonomously. Thus, dFRA is a novel member of the AP-1 family that resembles Fos structurally but whose mechanism of action is different from that of Fos.

Our results also indicate that the mixture of dFRA and dJRA forms a more stable protein–DNA complex and activates transcription to a greater extent than either of the proteins alone. These experiments provide the first direct evidence that Fos- and Jun-related proteins can activate transcription synergistically. One simple explanation for the observed synergy is that the dFRA–dJRA complex is bound more stably to the AP-1 site than either of the two proteins alone. Indeed, our EMSA results would support this model. However, it is risky to make a comparison between our in vitro transcription assay and the DNA-binding reaction, because the in vitro transcription reaction contains additional proteins, such as general transcription factors, that may contribute to the transcriptional synergism in vitro. Another possibility is that dFRA and dJRA proteins possess specific amino acid sequences that contribute to the synergistic activation. The fact that dFRA may act on its own or in combination with dJRA provides an additional level of regulation of gene expression in the developing organism.

dFRA is a relative of Fos

The amino acid sequences of the basic region and leucine repeat of dFRA are more like Fos than Jun. We find, however, that dFRA is mechanistically more like Jun than Fos in its transcriptional activation and DNA-binding properties. These unexpected results raise questions about the structural features of dFRA that enable it to recognize the AP-1 site and activate transcription on its own where Fos cannot. A number of studies have demonstrated that the leucine repeats confer the dimerization function and that dimerization is a prerequisite for DNA binding. Thus, the fact that Fos cannot recognize the AP-1 site on its own has been attributed to an inability to homodimerize (Kouzarides and Ziff 1988; Ransone et al. 1989, Turner and Tjian 1989). The demonstration that Fos could homodimerize when its leucine repeat was replaced with that of GCN4 and that this chimeric molecule could recognize the AP-1 site on its own (Kouzarides and Ziff 1988, Sellers and Struhl 1989) supported the contention that amino acids preventing Fos from dimerizing are probably in the leucine repeat or near the repeat, but the precise residues are as yet unidentified. We speculate that dFRA recognizes the AP-1 site on its own by virtue of an inherent potential to form homodimers.

One suggestion as to why Fos does not bind the AP-1 site on its own is that Fos has few hydrophobic residues within its leucine repeat domain (O'Shea et al. 1989; Ransone et al. 1989). The high degree of hydrophobicity within the Jun dimerization domain, specifically in residues that comprise the 4-3 repeat [using the nomenclature for coiled coils, O'Shea et al. 1989 and references therein], would account for its ability to form stable homo- as well as heterodimers. In this regard, it is interesting to note that dFRA contains a valine where Fos contains a threonine residue, and dFRA contains a glycine where Fos contains a lysine residue [Fig. 1C]. Thus, it is possible that these residues in dFRA, which may contribute to the hydrophobicity along one face of the putative α-helix, may contribute to homodimerization. Furthermore, it is also possible that dFRA possesses sequences in remaining portions of the molecule that would permit dimerization. A systematic mutagenesis of dFRA should provide information concerning the structural features of a Fos-related antigen that determine its ability to act autonomously.

Although dFRA binds the AP-1 site in the absence of dJRA, we observe that the apparent affinity of dFRA for the AP-1 site is weaker than that of dJRA. In some ex-
experiments, we have observed that more AP-1 oligonucleotide is complexed with dFRA at temperatures below 20°C, whereas the formation of dJRA–AP-1 site complexes is not as temperature-dependent. From these observations, we speculate that the temperature dependence of the dFRA–DNA complex suggests that this complex is not as stable as the dJRA–DNA complex. It is unclear how this complex stability affects transcription, as both proteins activate transcription in reactions carried out at 21°C. However, there are other proteins in the transcription reaction that are likely to stabilize transcription complexes.

**Drosophila AP-1 family**

The isolation of dFRA and dJRA cDNAs from *Drosophila* opens an alternative pathway to understanding the functions of Fos and Jun proto-oncogenes in development. It is possible that dFRA and dJRA are the only AP-1 family members in *Drosophila*, because we did not detect any additional AP-1 cDNAs in our library screens, nor did we detect any additional AP-1 binding-site activity during protein purification. In addition to *Drosophila*, members of the AP-1 family have now been isolated from such diverse species as yeast (Hope and Struhl 1985), plants (Katagiri et al. 1989) that are involved in a number of distinct cellular activities ranging from amino acid biosynthesis (Hope and Struhl 1985) to regulation of a fat-specific gene (Distel et al. 1987).

Another than the basic region and leucine repeat motifs, AP-1 family members bear few similar amino acid sequences. Jun is known to possess a transcriptional activation domain that is rich in prolines and acidic amino acids (Bohmann and Tjian 1989), and the transcriptional activation domain of GCN4 is highly acidic (Hope and Struhl 1985). Thus, we might have expected that dJRA (or dFRA) would contain a similar identifiable transcription activation domain. However, neither of the *Drosophila* AP-1 proteins appears to possess significant sequences in common with Fos and Jun outside of the conserved DNA-binding and dimerization domains. This finding is in keeping with the structures of many other AP-1 proteins. For example, the fra-1 cDNA that encodes a FRA from rat fibroblasts contains amino acids that are 77% conserved with the leucine repeat and basic domains of Fos but bears no similarity elsewhere in the molecule (Cohen and Curran 1988). In addition, the yeast AP-1 cDNA (yAP-1), which has been reported to encode a protein related to Jun, is structurally conserved only within the leucine repeat and basic domains (Moye-Rowley et al. 1989). Thus, these two sequence motifs have been conserved throughout evolution and confer on AP-1 proteins the ability to participate in diverse cellular pathways while using similar biochemical mechanisms.

**Materials and methods**

**Purification of dFRA and dJRA and peptide sequencing**

dFRA and dJRA proteins (~3 μg of each protein) were purified from *Drosophila* embryo extracts by sequence-specific DNA affinity chromatography and separated by reverse-phase high-performance liquid chromatography (HPLC), as described previously [Perkins et al. 1988], except that cysteine residues were alkylated with 1 M 4-vinylpyridine in isopropanol for 2 hr at 37°C immediately prior to HPLC injection. Following HPLC, dFRA and dJRA proteins (which elute from the column with ~50% and 50% acetonitrile in 0.1% trifluoroacetic acid (TFA), respectively) were lyophilized to dryness. The pellets were resuspended in 100 mM ammonium bicarbonate [100 μl] and incubated with trypsin (40 ng) for 12–16 hr at 37°C. To separate the resulting peptides, the entire fraction was applied directly to an HPLC C18 column (300A, 2.1 x 150 mm, Vydac) equilibrated previously with 0.1% TFA. The peptides were eluted with a linear gradient of acetonitrile and sequenced by use of the Applied Biosystems Protein Sequencer 477A.

**Isolation of a recombinant clone encoding dFRA**

Two oligonucleotides [1, 5'-CCGCGGGGATCTCCCTCCTCGGACCTAG-3' and 2, 5'-AAGGAGATCTAGGTTGACCGAGCAG-3'] were deduced from the amino acid sequences of two tryptic peptides [1, VLPNAIDVLGMIPTGVS and 2, KGIEVLTNS] of dFRA by use of a *Drosophila* codon usage table (Lathe 1985; Streek et al. 1986). The oligonucleotides were labeled at the 5' end with [γ-32P]ATP amnylytransferase kinase and used to screen a cDNA library in agtl1 prepared from *Drosophila* embryos between 9 and 12 hr of development (kindly provided by K. Zinn). For this purpose, ~700,000 λ plaques were plated at a density of 50,000 plaques per plate [150 x 20 mm] and then transferred to nitrocellulose. The filters were hybridized with radioactive probes, in 5 x Denhardt's/50 mM NaPO4 (pH 6.8), 6 x SSC at 37°C for 16 hr and then washed at 65°C (oligo 1) or at 50°C (oligo 2) in 2 x SST/0.5% SDS. A single dFRA cDNA was isolated by this method.

**Isolation of recombinant clones encoding dJRA**

Two oligonucleotides [3, 5'-CTTICAAGTIGAACGCTCCATGCA-3' and 4, 5'-ICCGAAGTCIACGTTCTCICCCCTTCAG-3'] were deduced from peptide sequences [3, LKGENVDLASSV, and 4, AGPVT-EQD] and labeled as described for dFRA. These oligonucleotides were then used to screen a *Drosophila* genomic library in agt10 (kindly provided by K. Moses). For this purpose, ~40,000 phage plaques were plated at a density of 20,000 plaques per plate [150 x 20 mm], transferred to nitrocellulose, and hybridized with radioactive oligonucleotides (3 and 4) by use of conditions described for dFRA. The filters were then washed at either 56°C (oligo 3) or 60°C (oligo 4) in buffers described for dFRA. Eleven positively hybridizing plaques were visualized by autoradiography and further purified. λ DNA was prepared, digested with Rsal, Haelll, and Aul, and subcloned into M13 to confirm the identities of these clones by DNA sequencing (Sanger et al. 1977). Six of these clones contained the sequences of the oligonucleotides for screening.

To obtain the dJRA cDNA clone, one of the genomic dJRA cDNA fragments in M13 was then used as a probe to screen a cDNA library prepared from *Drosophila* embryos between 3 and 12 hr of development (kindly provided by L. Kauvar). To label the dJRA genomic insert in M13, single-stranded DNA was prepared and annealed to the universal M13 primer. Labelled DNA was synthesized in the presence of α-32PdCTP and the Klenow fragment of *E. coli* DNA polymerase I. The DNA was then digested with EcoRI, and the labeled cDNA fragment
was purified by 5% polyacrylamide gel electrophoresis. This labeled probe was used to screen the cDNA library by the same method described for dFRA, except that the wash was carried out at 65°C. Two cDNA clones were obtained. Restriction enzyme analysis indicated that the two cDNAs were related. The longest of the two was analyzed further by DNA sequencing.

**Sequencing of dFRA and dJRA cDNAs**

To sequence the dFRA and dJRA cDNAs, λ DNA containing the cDNAs was prepared, and the cDNA inserts were removed by digestion with EcoRI and subcloned into pBluescript-SK (Stratagene) to create dFRA-SK and dJRA-SK. Nested deletions in the cDNAs were then prepared by the method of Henikoff (1987), except that α-thio-dNTPs (Stratagene) were used to prevent bidirectional exonuclease III digestion. Deletion mutants containing overlapping segments of the cDNAs were sequenced (Sanger et al. 1977) by use of the M13 universal primer.

**Expression of dFRA and dJRA in E. coli**

To create constructs that would express dFRA and dJRA proteins, NdeI sites were introduced at the initiating ATG codons in dFRA-SK and dJRA-SK by oligonucleotide-directed mutagenesis (Kunkel 1985). This resulted in the fortuitous introduction of a second NdeI site immediately downstream of the dJRA ORF. An NdeI site is present downstream of the wild-type dFRA ORF. By digestion of these constructs with NdeI, the cDNAs were removed. They were then subcloned into a unique NdeI site downstream from the φ10 promoter for T7 RNA polymerase in bacterial expression vector pAR3040 (Rosenberg et al. 1987). These constructs [dFRA-3040 and dJRA-3040] were used to transform E. coli strain BL21, which contains a chromosomal copy of the T7 RNA polymerase gene. Induction of the gene encoding T7 polymerase was induced by the method of Studier and Moffatt (1986).

**Purification of dFRA and dJRA from E. coli extracts**

Extracts ([5 ml, ~15 mg of protein/ml]) were prepared as described (Hoey and Levine 1988) from E. coli (500 ml) harboring the dAP-1 cDNAs, except that the buffer used was 25 mM HEPES-KOH (pH 7.6), 0.1 mM EDTA, 12.5 mM MgCl₂, 10% (vol/vol) glycerol, 0.1 M KCl (0.1 M HEMG), and dFRA and dJRA were fractionated in the supernatant of the 35K centrifugation. The salt concentration of the supernatant was adjusted to 0.3 M KCl and was applied to a DEAE-Sepharose CL-6B (Pharmacia) column (1 ml) that had been equilibrated previously with 0.3 M HEMG. The column was washed with three volumes of 0.3 M HEMG. The flowthrough (5.4 ml, ~10 mg of protein/ml) and wash (3 ml, ~3 mg of protein/ml) were pooled, and either 16 µg [for dFRA] or 156 µg [for dJRA] of poly[d(I-C)] was added. The conductivity was adjusted to 0.1 M HEMG by the addition of HEMG, and the fractions (24 ml) were applied to DNA affinity columns (0.5 ml) containing an AP-1 recognition site oligonucleotide [Perkins et al. 1988]. The columns were washed with 5 column volumes of 0.1 M HEMG and eluted stepwise with 3 volumes of 0.2 M HEMG, 2 volumes of 0.5 M HEMG, and 3 volumes of 1 M HEMG. Fractions were analyzed by SDS-PAGE. We estimate that from 500 ml of E. coli [OD₆₀₀ = 0.6–0.8], we obtain ~9 µg of dJRA and 5 µg of dFRA protein.

**In vitro translation of dFRA and dJRA and mobility-shift analysis**

For transcription and translation in vitro, the cDNAs in dFRA–3040 or dJRA–3040 were excised with NdeI, digested with mung bean exonuclease (Stratagene), and subcloned into the SruI site of pBSal (Norman et al. 1988). Transcription and translation in vitro, as well as mobility-shift analyses, were conducted as described [Turner and Tjian 1989] except that the DNA-binding reactions and gel electrophoresis were carried out at 4°C. In cotranslation experiments with dFRA and dJRA, the amount of RNA from each cDNA was one-half the amount used when these proteins were translated individually.

**Nonradioactive in situ hybridization experiments**

For nonradioactive in situ hybridization experiments, single-stranded DNA probes were synthesized from the dFRA cDNA by the polymerase chain reaction in the presence of digoxigenin-labeled dUTP (Boehringer–Mannheim, N.H. Patel and C.S. Goodman, unpubl.). Hybridization and detection were carried out by use of the protocols of Tautz and Pfeifle (1989) and the Boehringer–Mannheim Genius kit. This nonradioactive procedure provides a much finer level of resolution than radioactive probes and allows for expressing cells to be located in intact embryos instead of tissue sections. The specificities of these signals and the signals observed by using radioactive probes were confirmed by hybridization with probes to the opposite DNA strand (data not shown).

**Acknowledgments**

We acknowledge Willy Liao, Myung Shin, Gina Dailey, and Bobbi Johnson for their technical support. We thank Corey Goodman and Gerry Rubin and many people from their labs and from the Tjian lab for helpful discussions and technical expertise, especially Matthew Freeman, Hilary Clark, and Todd Laverty for the in situ hybridization experiments. We extend special thanks to Sharyn Endow and her laboratory for providing chromosomal DNA from the 99B(9-10) locus and for many helpful conversations. We appreciate the critical reading of this manuscript by Vijay Baichwal, Richard Turner, and Al Courey. We are also grateful to Karen Ronan for typing this manuscript and preparation of the figures. K.P. is supported by a grant from the Damon Runyon–Walter Winchell Cancer Research Fund (DRG-931).

**References**

Adamson, E.D. 1987. Oncogenes in development. Development 99: 449–471.

Bender, W. and M. Peifer. 1987. Oncogenes take wing. Cell 50: 519–520.

Bishop, J.G. III and V.G. Corces. 1988. Expression of an activated ras gene causes developmental abnormalities in transgenic Drosophila melanogaster. Genes Dev. 2: 567–577.

Bodmer, R., S. Barbel, S. Shepard, J.W. Jack, L.Y. Jan, and Y.-N. Jan. 1987. Transformation of sensory organs by mutations of the cut locus of D. melanogaster. Cell 51: 293–307.

Bohmann, D. and R. Tjian. 1989. Biochemical analysis of transcriptional activation by Jun: Differential activity of c- and v-jun. Cell 59: 709–711.

Bohmann, D., T.J. Bos, A. Admon, T. Nishimura, P.K. Vogt, and R. Tjian. 1987. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238: 1386–1392.

Chiu, R., W.J. Boyle, J. Meek, T. Smeal, T. Hunter, and M. Karin. 1988. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 54: 541–552.

Cohen, D.R., and T. Curran. 1988. fra-1: A serum-inducible,
cellular immediate early gene that encodes a fos-related antigen. Mol. Cell. Biol. 8: 2063–2069.

Curran, T. and B.R. Franza, Jr. 1988. Fos and Jun: The AP-1 connection. Cell 55: 395–397.

Curran, T. and N.M. Teich. 1982. Candidate product of the FBJ murine osteosarcoma virus oncogene: Characterization of a 55,000-dalton phosphoprotein. J. Virol. 42: 114–122.

Deschamps, J., R.L. Mitchell, F. Meijlink, W. Kuiper, D. Schubert, and I.M. Verma. 1985. Proto-oncogene fos is expressed during development, differentiation, and growth. Cold Spring Harbor Symp. Quant. Biol. 50: 733–745.

Distel, R.J., H.-S. Ro, B.S. Rosen, D.L. Groves, and B.M. Spiegelman. 1987. Nucleoprotein complexes that regulate gene expression in adipocyte differentiation: Direct participation of c-fos. Cell 49: 835–844.

Dynlacht, B.D., L.D. Attardi, A. Admon, M. Freeman, and R. Tian. 1989. Functional analysis of NTF-1, a developmentally regulated Drosophila transcription factor that binds neuronal cis elements. Genes Dev. 3: 1677–1688.

Gentz, R., F.J. Rauscher, III, C. Abate, and T. Curran. 1989. Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains. Science 243: 1695–1699.

Ghysen, A., C. Damby-Chaudiere, E. Aceves, L.-Y. Jan, and Y.-N. Jan. 1986. Sensory neurons and peripheral pathways in Drosophila embryos. Wilhelm Roux's Arch. Dev. Biol. 195: 281–289.

Halazonetis, T.D., K. Georgopoulos, M.E. Greenberg, and P. Leder. 1988. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55: 917–924.

Hanley, M.R. 1988. Proto-oncogenes in the nervous system. Neuron 1: 175–182.

Hauser, C.A., A.L. Joyner, R.D. Klein, T.K. Learned, G.R. Martin, and R. Tian. 1985. Expression of homologous homeobox-containing genes in differentiated human teratocarcinoma cells and mouse embryos. Genes Dev. 43: 19–28.

Heberlein, U., B. England, and R. Tian. 1985. Characterization of Drosophila transcription factors that activate the tandem promoters of the alcohol dehydrogenase gene. Cell 41: 965–977.

Henikoff, S. 1987. Unidirectional digestion with exonuclease III in DNA sequence analysis. Methods Enzymol. 155: 156–165.

Hoey, T. and M. Levine. 1988. Divergent homeobox proteins recognize similar DNA sequences in Drosophila. Nature 332: 858–861.

Hope, I.A. and K. Struhl. 1985. GCN4 protein, synthesized in vivo, binds HIS 3 regulatory sequences: Implications for general control of amino acid biosynthetic genes in yeast. Cell 43: 177–189.

Jones, R.H., S. Moreno, P. Nurse, and N.C. Jones. 1988. Expression of the SV40 promoter in fission yeast: Identification and characterization of an AP-1-like factor. Cell 53: 659–667.

Katagiri, F., E. Lam, and N.-H. Chua. 1989. Two tobacco DNA-binding proteins with homology to the nuclear factor, CREB. Nature 340: 727–729.

Kunkel, T.A. 1985. Rapid and efficient site-specific mutagenesis without phenotype selection. Proc. Natl. Acad. Sci. U.S.A. 82: 488–492.

Kouzarides, T. and E. Ziff. 1988. The role of the leucine zipper in the Fos-Jun interaction. Nature 336: 646–651.

Kouzarides, T. and E. Ziff. 1988. The role of the leucine zipper in the Fos-Jun interaction. Nature 336: 646–651.

Landschulz, W.H., P.F. Johnson, and S.L. McKnight. 1988. The dFRA is a transcriptional activator.
Perkins et al.

Schuermann, M., M. Neuberg, J.B. Hunter, T. Jenuwein, R.-P. Ryseck, R. Bravo, and R. Müller. 1989. The leucine repeat motif in Fos protein mediates complex formation with Jun/AP-1 and is required for transformation. *Cell* 56: 507–516.

Sellers, J.W. and K. Struhl. 1989. Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping “leucine zippers.” *Nature* 341: 74–76.

Shilo, B.-Z. 1987. Proto-oncogenes in *Drosophila melanogaster*. *Trends Genet.* 3: 69–72.

Steward, R. 1987. *Dorsal*, an embryonic polarity gene in *Drosophila*, is homologous to the vertebrate proto-oncogene, c-rel. *Science* 238: 692–694.

Streck, R.D., J.E. MacGaffey, and S.K. Beckendorf. 1986. The structure of hobo transposable elements and their insertion sites. *EMBO J.* 5: 3615–3623.

Studier, J.W. and B.A. Moffatt. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J. Mol. Biol.* 189: 113–130.

Tautz, D. and C. Pleifle. 1989. A non-radioactive in situ hybridization method for the localization of specific RNAs in *Drosophila* embryos reveals translational control of the segmentation gene *hunchback*. *Chromosoma* 98: 81–85.

Turner, R., and R. Tjian. 1989. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional c-Fos-c-Jun heterodimers. *Science* 243: 1689–1694.

Wilkinson, D.G., S. Bhatt, R.-P. Ryseck, and R. Bravo. 1989. Tissue-specific expression of c-jun and junB during organogenesis in the mouse. *Development* 106: 465–471.

Yamamoto, A.H., D.J. Komma, C.D. Shaffer, V. Pirotta, and S.A. Endow. 1989. The *claret* locus in *Drosophila* encodes products required for eye color and for meiotic chromosome segregation. *EMBO J.* 8: 3543–3552.

Zerial, M., L. Toschi, R.P. Ryseck, M. Schuermann, R. Müller, and R. Bravo. 1989. The product of a novel growth factor activated gene, *fosB*, interacts with JUN proteins enhancing their DNA binding activity. *EMBO J.* 8: 805–819.
The Drosophila Fos-related AP-1 protein is a developmentally regulated transcription factor.

K K Perkins, A Admon, N Patel, et al.

Genes Dev. 1990, 4:
Access the most recent version at doi:10.1101/gad.4.5.822

References
This article cites 58 articles, 22 of which can be accessed free at:
http://genesdev.cshlp.org/content/4/5/822.full.html#ref-list-1

License

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.